Summa animali da compagnia N. 4 - 2022 del Maggio 2022 - Monotematico

Il DNA tumorale circolante,un biomarker del futuro in oncologia veterinaria

• 1. Alix-Panabières C, Pantel K. Clinical Applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6:479-491.
• 2. Beck J, Hennecke S, Bornemann-Kolatzki K et coll. Genome aberrations in canine mammary carcinomas and their detection in cell-free plasma DNA. PLoS One. 2013;8:e75485.
• 3. Butler TM, Spellman PT, Gray J. Circulating-tumor DNA as an early detection and diagnostic tool. Curr. Opin. Genet. Dev. 2017;42:14-21.
• 4. Hedan B, de Brito C, Guillory AS. Cancer chez le chien : prédispositions raciales et formes familiales. Point Vét. 2015;(354):54-62.
• 5. Hedan B, Rault M, Abadie J et coll. PTPN11 mutations in canine and human disseminated histiocytic sarcoma. Int. J. Cancer. 2020;147:1657-1665.
• 6. Hendricks WPD, Zismann V, Sivaprakasam K et coll. Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. PLoS Genet. 2018;14:e1007589.
• 7. Mochizuki H, Shapiro SG, Breen M. Detection of BRAF mutation in urine DNA as a molecular diagnostic for canine urothelial and prostatic carcinoma. PLoS One. 2015;10:e0144170.
• 8. Poorman K, Borst L, Moroff S et coll. Comparative cytogenetic characterization of primary canine melanocytic lesions using array CGH and fluorescence in situ hybridization. Chromosome Res. 2015;23:171-186.
• 9. Prouteau A, Chocteau F, de Brito C et coll. Prognostic value of somatic focal amplifications on chromosome 30 in canine oral melanoma. Vet. Comp. Oncol. 2020;18:214-223.
• 10. Saukkonen K, Lakkisto P, Varpula M et coll. Association of cell-free plasma DNA with hospital mortality and organ dysfunction in intensive care unit patients. Intensive Care Med. 2007;33:1624-1627.
• 11. Saukkonen K, Lakkisto P, Pettilä V et coll. Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. Clin. Chem. 2008;54:1000-1007.
• 12. Schwarzenbach H, Hoon DSB, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat. Rev. Cancer. 2011;11:426-437.
• 13. Tagawa M, Tambo N, Maezawa M et coll. Quantitative analysis of the BRAF V595E mutation in plasma cell-free DNA from dogs with urothelial carcinoma. PLoS One. 2020;15:e0232365.
• 14. Takada M, Smyth LA, Thaiwong T et coll. Activating mutations in PTPN11 and KRAS in canine histiocytic sarcomas. Genes (Basel). 2019;10:505.
• 15. Thaiwong T, Sirivisoot S, Takada M et coll. Gain-of-function mutation in PTPN11 in histiocytic sarcomas of Bernese mountain dogs. Vet. Comp. Oncol. 2018;16:220-228.
• 16. VetBloom. Canine cancer detection BRAF mutation detection assay. 2018. https://blog.vetbloom.com/wp-content/uploads/2018/01/CADET-BRAF-mutationdetection-kit.pdf
• 17. Wong K, van der Weyden L, Schott CR et coll. Cross-species genomic landscape comparison of human mucosal melanoma with canine oral and equine melanoma. Nat. Commun. 2019;10:353.
• 18. Wu TH, Hsiue EHC, Yang JCH. Opportunities of circulating tumor DNA in lung cancer. Cancer Treat. Rev. 2019;78:31-41.
• 19. Yeung KT, More S, Woodward B et coll. Circulating tumor DNA for mutation detection and identification of mechanisms of resistance in non-small cell lung cancer. Mol. Diagn. Ther. 2017;21:375-384.